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ABSTRACT
Many patients with head and neck squamous cell carcinoma present with regional spread to the 
cervical lymph nodes. Lymph nodes metastases are today the most important factor influen-
cing both the treatment and outcome for this type of cancer. The developments of new cancer 
treatments and especially immune oncology with the use of new antibodies have changed the 
field of cancer medicine. In order to fully benefit from this development we have to improve 
the select patients for the various treatments that can be offered. The overall goal of this thesis 
is to study the immune responses in tumour tissue, lymph nodes and blood in patients with 
head and neck cancer with focus on leukocytes, flow cytometry detection of tumour cells and 
T cell activity.  
Paper I delineates the leukocyte ratios in blood from patients with oropharyngeal cancer in an 
attempt to correlate this with relevant clinical findings. Patients with oropharyngeal cancer 
displayed signs of  increased systemic inflammation. Generally, large tumours seemed to be 
associated with a high neutrophil to monocyte ratio whereas patients with metastatic node 
spread showed a low corresponding value.
Paper II characterizes different neutrophil subsets in head and neck cancer and investigates 
their role in the disease. A specific neutrophil subset, CD16highCD62Ldim appeared to have 
anti-tumour  properties, with the ability to inhibit cancer cell migration and proliferation and 
to induce apoptosis. Further, the elastase in the activated neutrophils created neutrophil extra- 
cellular traps and a high rate of  CD16highCD62Ldim neutrophils corresponded to a better 
survival. 
Paper III is a proof-of-concept study that appraises flow cytometry as a method for detecting 
lymph node metastases in oral cancer. The results could be presented within 6 hours of the 
time of biopsy and the data correlated precisely with the clinical histopathologic investigation 
performed in parallel. In addition, the obtained data indicated that flow cytometry can be a very 
sensitive tool also for finding micro metastases.
Paper IV was made in order to establish a reliable and clinically useful protocol for sentinel 
lymph node biopsies in elective neck dissections in patients with oral cancer. Various tech-
niques for identification of sentinel nodes in oral cancer were evaluated in a clinical setting. 
A combination of techniques was found to constitute a reliable, clinical adaptable work con-
cept. An injection of radioactive technetium Tc99m carried on tilmanocept started the process. 
The lymph nodes were visualized with SPECT-CT before surgery and with indocyanine green 
fluorescence dye in combination with a hand-held gamma probe during surgery. 
Paper V evaluates the immune response in lymph nodes of oral cancer patients with focus on 
T lymphocyte activation and linkage to PD-1/PD-L1 expression Lymph node metastses in 
oral cancer exhibited a higher level of activated T cells than cancer free lymph nodes. CD69, 
a marker of T cell activity was generally higher in sentinel lymph nodes than in regular 
nodes. PD-L1 on tumour cells did not correlate to the expression of activation markers on 
T lymphocytes in the tumour. CD8+ T lymphocytes with high CD71+PD-1 expression were 
more abundant in the tumours than in the sentinel nodes. Altogether this indicates that 
immunologic activity of the sentinel node might be used to predict selection for immunological 
treatment.
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AIMS
The overall aim of this thesis is to study the immune response in tumour tissue, lymph nodes 
and blood in patients with head and neck cancer with focus on leukocytes, flow cytometry 
detection of tumour cells and T cell activity. Specifically to:
- Correlate the leukocyte ratios in blood from patients with oropharyngeal  
cancer to relevant clinical findings.
- Characterize different neutrophil subsets in head and neck cancer and to  
investigate their role in the disease.
- Appraise flow cytometry as a method to detect cancer cells lymph nodes in oral 
cancer patients. 
- To establish a reliable and clinically useful protocol for sentinel lymph node 
biopsy in elective neck dissections in patients with oral cancer
- Evaluate the immune response in  lymph nodes of oral cancer patients with 
focus on T lymphocytes activation and linkage to PD-1/PD-L1 expression 
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BACKGROUND
Head and Neck Cancer
Head and neck cancer (HNC) is a diverse group of cancers that appears in the nose, mouth, 
throat, larynx, sinuses and salivary glands. The most common type is squamous cell carcinoma 
(HNSCC). Well known risk factors are smoking and alcohol consumption, in the tonsils and 
the base of tongue the development of squamous cell carcinomas are closely related to human 
papilloma virus (HPV). HNSCC is known to have immunosuppressive activity (1).
HNC is classified using the TNM system where, T significes  the extent of the primary tumour, 
N the extent of  regional lymph node metastasis M and the absence or presence distant metas-
tasis. A subdivision is pTNM, pathological classification, which takes the histological analysis 
in consideration. Stage is a concept commonly used, where the categories has been condensed 
into groups, and each group is more or less homogeneous with regard to survival (2).
Oropharyngeal Cancer
Oropharyngeal squamous cell carcinoma (OPSCC) appears mainly in the area of the tonsils and 
the lingual tonsil at the base of the tongue and share morphological and histological similarities. The 
surface is covered with non-keratinized squamous stratified epithelium with underlying lymphoid 
tissue. HPV infection is the most common risk factor for oropharyngeal cancer (3,4). The local 
symptoms may be modest, and the tumours metastasize early to regional lymph nodes. The-
refore, a lump in the neck is often the first symptom. The incidence of oropharyngeal cancer 
in 2012 was globally 1,4 per 100 000 inhabitants and year (2,3 men versus 0,5 women) (5). In 
Sweden the incidence is 3,6/100 000 inhabitants per year and 70% are men (6).
Human Papilloma Virus
There are many types of HPV divided into low risk and high risk viruses depending on their 
capacity to induce cancer. 12 HPV subtypes are oncogenic in humans and the most common in 
oropharyngeal cancers is HPV16. All HPV have a double-stranded DNA genome that encodes 
regulatory proteins. In high risk HPV the regulation proteins E6 and E7 are oncogenes and 
their intervention with the cellular tumour suppressor proteins, p53 and Rb leads to dysregula-
tion of the cell cycle control. When this occurs the kinase inhibitor p16 will be overexpressed 
(7). HPV is found in 40-100 % of tonsillar and base of tongue cancers in the western world (8) 
and in about 75% in Sweden(6,9). The incidence for HPV associated OPSCC has increased 
in the last decades (10,11) and has settled at a high level in Stockholm during the last decade 
(9). HPV is a strong favourable prognostic marker for patients with tonsillar or base of tongue 
cancer (4,12,13).
Treatment of Oropharyngeal Cancer
The protocol for treatment includes radiotherapy frequently combined with targeted therapy/
Epidermal Growth Factor Receptor antibodies (EGFRab) and sometimes chemotherapy. Base 
of tongue cancer patients in some regions of Sweden also receive brachytherapy. If there is a 
suspicion of residual lymph node metastasis after the oncological treatment a neck dissection is 
performed (14). PD1/PD-L1 therapy could also have a role in oropharyngeal cancer (15). Since 
patients with HPV positive OPSCC, especially non-smokers, have such a good prognosis it has 
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been suggested- and trails are ongoing- where the treatment could be de-escalated for selected 
patients (16). There are vaccines against HPV and in Sweden they are included in the general 
vaccination program for girls since 2010 (17) and may be so for boys in the near future (18).
Oral Cancer
Oral cancer may arise in the buccal mucosa, the upper and lower gum, the hard palate, the 
mobile tongue and the floor of the mouth. Tongue cancer located in the mobile part of the 
tongue, i.e. the frontal 2/3 and are referred to as mobile tongue cancer or oral tongue cancer. 
The mobile tongue consists of several muscular layers and the surface is covered by stratified 
squamous epithelium with papillae, taste buds and mucus glands. 
Squamous cell carcinoma of the oral tongue is the most common oral cancer. The cancer 
frequently appears as a painless lesion on the lateral border of the tongue. It is correlated 
to smoking, alcohol and betel nut use. HPV infection is rare (19–22). The majority of the 
mobile tongue cancers are discovered at an early stage, T1-T2 N0. However loco regional 
recurrence is common and the prognosis is poor, with an overall survival of only 50-65 % (23,24) 
The estimated incidence 2012 of oral cavity cancer globally was 2.7 per 100,000 inhabitants and 
year (3.7 in men and 1.8 in women) and differs substantially with location, age and sex (5). In 
Sweden mobile tongue cancer  presents with 140 cases each year (6). The incidence  of  tongue 
cancer has increased in women and all age groups except young men the last decades (25).
Treatment of Oral Cancer
The standard treatment of oral cancer is surgical resection of the primary tumour. If there are no 
detectable regional lymph node metastases at diagnosis, N0, there are two treatments options 
for the lymph nodes; elective neck dissection (END) or watchful waiting with therapeutic neck 
dissection at regional relapse of the cancer. Occult metastases are common in the neck of 
T1-T2, N0 patients (classified with radiology, before surgery) and have led to inconsistency of 
best option to treatment (26). A large prospective study showed a higher overall survival (OS) 
and disease free survival (DFS) for patients treated with an END as compared to watchful 
waiting (27). At our hospital only 6% of stage I (T1 N0) patients had a positive node in the 
END whereas stage II (T2 N0) patients had 41% occult metastases in their neck dissections 
specimens (28).
If a metastasis is found the patient usually receives external radiation towards the neck and 
depending on the surgical resection margin of the primary tumour and the Brandwein score 
(29) the patient can receive external radiation and/ or Brachycatheter radiation therapy at the 
local site (30).
Metastasis Detection
Prior to surgery all oral cancer patients are investigated with a CT scan covering the skull base, 
the neck and lungs to check for metastases and if needed PET-CT and MRI. If any suspicious 
neck nodes are found, ultrasound guided fine needle aspiration cytology is performed. Accor-
ding to the results a plan for the surgery is set up. Histopathological analysis of resected lymph 
nodes can confirm or exclude metastatic spread. A typical neck dissection specimen contains 
15 to 30 lymph nodes. Usually only one cross-section of each individual node is screened by a 
pathologist.
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Lymph Nodes Metastases
Many head and neck cancer patients present with regional metastases in the neck whe-
reas distant metastases are rare. Lymph node metastases have a major impact on treat-
ment as well as on the outcome for the patient. Neck dissection has been performed sin-
ce the beginning of the twentieth century. In 1991 the American Society of Head and 
Neck developed a classification system, upgraded twice, that is widely used today. It is ba-
sed on a radical neck dissection procedure. Today a modified neck dissection procedu-
re, in which you preserve one or more of important non-lymphatic structures, is more 
common. A selective neck dissection procedure preserves one or more groups of lymph nodes 
compared to a radical neck dissection (31,32).
The lymphatic flow from the mobile part of the tongue drains mainly into the deep cervical 
glands lying between the posterior belly of the digastric muscle and the superior belly of the 
omohyoid muscle. The frontal part and the caudal part of the tongue drain to the submental 
glands through the mylohyoid muscle (33,34).
         
A
  
B
Figure 1: Cervical lymph node drainage and surgical regions of the neck. (A) The deep lymph nodes of the 
neck. Picture from “The practice of surgery” (1910). (B) The surgical regions of a neck dissection procedure. 
Picture made by Helena Torhage.
The Immune System
In the last decades more attention has been raised towards the role of inflammation in cancer 
diseases and it is now considered a hallmark of cancer. Immunotherapy is a potent treatment 
in many forms of cancer diseases (35,36).
The immune system consists of cells and molecules in our body that defend us against foreign 
harmful pathogens. In some situations the normal immune mechanisms are able to cause injury 
and disease, so-called autoimmune responses. Traditionally it has been divided into the inna-
te immune system, an early, rapid and mechanic defence against pathogens and the adaptive 
immune system,  which is slow but more specific and effective. There is a close interaction 
between the systems (37).
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Innate Immunity
The first barrier of the innate system is the skin or the mucosa. The cellular defence of the 
innate systems includes monocytes, macrophages, granulocytes (neutrophils, basophils and eo-
sinophils) and dendritic cells. The Natural Killer cell (NK cell) is a T lymphocyte with killer 
skills, without binding to the Major Histocompatibility Complex (MHC) I complex and coun-
ted as an innate cell. The innate immunity is an early fast defence against foreign pathogens.
Neutrophils
Neutrophils play an important role for the acute inflammation and are essential for the innate 
immune responses. They react rapidly upon intruding pathogens and the production of neut-
rophils from the bone marrow is fast. Neutrophils are normally the most frequent leucocyte 
in the blood circulation. They migrate to the area of infection to phagocytose and kill bacteria. 
Their half time in blood is about 6-8 h but this might be extended when they migrate into in-
flamed tissues (38). After destroying bacteria, neutrophils undergo apoptosis and are cleared 
from the tissue by resident macrophages. Until recently neutrophils have been looked upon as 
a homogeneous group of cells, but new research has demonstrated different neutrophil subsets 
based on their expression of CD16 and CD62L. These are CD16dimCD62Lhigh - considered 
less mature since they have banded nuclear morphology characteristic of neutrophils derived 
from the bone marrow, CD16highCD62Lhigh - phenotypically normal mature neutrophils and 
CD16highCD62Ldim - thought to be activated and have a hyper segmented nuclei (39,40).
                          A
  
B
Figure 2:		(A)	Flow	cytometry	dot	plot	of	HNSCC.	(B)	Schematic	figure	illustrating	the	maturation	or	
activation	process	of	neutrophils	on	a	flow	cytometry	dot	plot.	Upper	left	quadrant;	immature	neutrop-
hils	express	CD62L	but	hardly	CD16,	upper	right	quadrant;	normal	neutrophils	express	both	CD62L	
and	CD16.	In	the	lower	right	quadrant;	activated	neutrophils	express	CD16	but	has	lost	CD62L	and	
in	the	left	lower	quadrant;	end	state	neutrophils	are	displayed.	Picture	B	is	republished	with	the	kind	
permission from Julia Arebro.
 
Adaptive Immunity
The adaptive immune system develops later than the innate immune system and is more speci-
fic. The adaptive immune response requires reactive B or T lymphocytes. The antigen presen-
tation cell (APC), most often a dendritic cell from the innate immunity, displays the captured 
antigen on the cell surface for recognition of the lymphocyte. The lymphocytes become acti-
vated, proliferate and differentiate into an effector cell that may eliminate the foreign pathogen. 
The B-lymphocytes create an antibody specific response, create a memory and have their ef-
fector function through antibodies. T lymphocytes are responsible for cell mediated immunity.
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T Cell Mediated Immunity
Roughly 30% of the circulating leukocytes are lymphocytes. A vast majority of the lymphocytes 
are situated in the lymphatic system. T and B lymphocytes develop from the same multipotent 
stem cell in bone marrow; the precursor to T lymphocyte migrates to the thymus where they 
mature to T lymphocytes. CD8+ or cytotoxic T lymphocytes are killer cells. The T cell receptor 
(TCR) on the cytotoxic T lymphocyte binds to the peptide presented on a MHC class I recep-
tor of the APC and activates and releases cytokines that will kill the target or trigger apoptosis. 
CD4+ or T helper lymphocytes assist in many cellular and humoral immune reactions. The 
TCR of the T helper cell binds to the peptide bound MHC class II. T helper cells produce 
cytokines and coordinate the immune response. 
Neutrophils and Lymphocytes
A differential count of leukocytes is an easy and fast routine blood sample. The ratio between different 
leucocytes gives more information about the type of immune response than an absolute count of a 
specific cell type. A neutrophil lymphocyte ratio (NLR) is counted and has been suggested to 
serve as a biomarker for cancer prognosis. In several subtypes of cancer a high pre-treatment 
NLR has been associated with a poor overall survival (41–43). 
Lymphocytes in Cancer
The lymphocyte reaction in oral and oropharyngeal cancers is well characterized at the tumour 
primary site and in the peripheral circulation but not in the lymph nodes. There is a decreased 
amount of  lymphocytes in blood in patients with HNSCC (44). The lymphocyte host response 
in the primary cancer tissue is part of the Brandwein histological risk model used as a prognos-
tic estimate, which influences treatment decisions. A strong lymphocyte response around the 
oral tumour is associated with better prognosis, presumably due to anti-tumoural cytotoxic T 
lymphocytes (45). A high level of CD4 and CD8 tumour infiltrating lymphocytes (TIL) impro-
ves overall survival in HNSCC (46). This phenomenon is seen in many solid tumours. It has 
further been shown that the morphological pattern of TILs are important and it differs between 
HPV positive and HPV negative cancers (47). 
Figure 3: T cell activation The APC presents an antigen in its MHC, 
recognized of the TCR at the T-cell (signal 1). Co-stimulation occurs through 
binding of B7-CD28 (signal 2) and cytokines from the APC to the T-cell 
(signal 3).  The T-cell becomes activated, (the pink arrow in the picture). 
Illustration made by Helena Torhage.
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Cancer Immunology
The immune system capacity to recognize and destroy transformed cells before they have for-
med tumours called immune surveillance (48). This concept was set in the 1950s and today we 
have learned that the immune response is ineffective against human cancer cells but important-
ly it can be reactivated and kill tumour cells. So why does the immune system fail to eradicate 
tumour cells? The tumour has developed various mechanisms to avoid the immune response 
for example, they lose the antigen expression and can no longer be recognized by the immune 
system and the tumour cells grow fast and spread fast which overwhelm the host immune sys-
tem.
At the tumour site dendritic cells pick up a tumour antigen and travel with the lymph draining 
system to the lymph node. At the lymph node the dendritic cells display present the antigen 
with a MHC I which is recognized by a TCR on a CD8+ T cell. Co-stimulators, from APC cells 
or the CD4+ T Cells are essential at the same time for the CD8+ T cell to be able to become 
antigen-specific activated. The activated CD8+ T cell then travels with the blood stream back to 
the primary tumour site and can fullfill its tumour destroying mission (49). (Figure 4) The CD4+ 
T cells are as mentioned above important in the activation of CD8+T Cells, they secrete tumour 
necrosis factor (TNF) and interferon – γ (INF- γ). The latter increases the MHC I expression 
on the tumour cell and can make it more sensitive for lysis by CD8+ T cells.
Regulation of the Immune Response
The tumours have ability to evade the host immunity and cause the cancer disease. To be able to 
prevent immune evasion it is important to understand the mechanisms behind it. If we could 
understand these evasion manoeuvres of the tumour would find a way for immunotherapy (50). 
The tumour evades antitumor responses from the T lymphocytes by engaging inhibitory molecu-
les, which normally function to prevent autoimmunity and regulate immune response to microbes. 
Cytotoxic T lymphocyte- associated protein 4 (CTLA-4) and programmed cell death protein-1 
(PD-1) are inhibitory pathways that are upregulated on TILs (51). The inhibitory mechanisms 
establish checkpoints in the immune response. (Figure 5) Exactly how these inhibitory pathways 
are used by the tumour cell is not clear, but PD-L1 (PD-Ligand-1) is commonly expressed on 
human cancer cells, they sometime have a PD-L1 gene amplification. TILs found to be in an 
exhausted, dysfunctional form first described in chronic viral infection. The exhausted cell have 
diminished functions and amplified CTLA-4, PD-1 and other inhibitory molecules expressed 
on their surface. Tumour cells can secrete Tumour Growth Factor- β (TGF-β) which may in-
hibit T cells and macrophage proliferation and effector functions. The tumour can also evade 
the host immunity by antigen loss, failure to produce antigens or mutations in the genes of the 
MHC, so the tumour antigen will not be presented to the T cell. These functions make the T 
cell unable to recognize the tumour.
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Figure 4: The tumour immunology circle. (1) At the tumour site the APC pick up a 
tumour antigen and (2) travel with the lymph drainage to the (3) lymph node was 
the activation of the T lymphocyte occurs. T lymphocyte travels with the blood stre-
am (4) to the primary tumour site (5) were the can function as killer CD8+ T cells. 
Illustration made by Helena Torhage
Figure 5: (A) PD-1 from the T cell and PD-L1 from the APC or a tumour cell block T-cell 
activation. (B) Anti PD-1 or anti-PD-L1 block the connection between the PD-1 and the PD-L1 
and the inhibition bondage breaks and the T-cell become activated and can destroy tumour 
cells. Illustration made by Helena Torhage
A
B
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Immunotherapy
The inhibitory mechanisms establish checkpoints in the immune response. Antibodies that 
block these inhibitory pathways have been developed and exhibit promising results as im-
munotherapy against the tumour cells. The drugs are therefore called checkpoint inhibitors. 
CTLA-4 normally binds to B7, a receptor at the APC necessary for co-stimulation to get a T 
lymphocyte activated, and disturbs the co-stimulation. When you add an anti CTLA-4 it binds 
to the CTLA-4 and the functional co-stimulation leads to activated CD8+ cells, ready to destroy 
tumour cells (51). PD-1 at the T cell and the PD-L1 at the tumour cell normally bind to each 
other which lead to inhibition of the CD8+ cell. When you add anti-PD-1 or anti-PD-L1 you 
break the bondage of PD-1/PD-L1 and the activated CD8+ cell can regain its function to destroy 
tumour cells (Figure 5). There is a lot of research going on about tumour vaccination strategies; 
so far the only tumour prophylactic vaccination is the HPV vaccination (52). Chimeric antigen 
receptor (CAR) T cells are the new immune therapy at the market for lymphoma and lymphatic 
leukaemia and studies are ongoing for solid tumours. The patient’s own T cells  are used and 
in the lab a genetically engineered tumour antigen receptors together with co stimulators are 
added, then the whole vector is returned back to the patient. The T cell can now recognize the 
tumour antigen, with its new receptor and thereafter attack the tumour cell (53).
Immunology and Chemo Radiotherapy 
The amount of lymphocytes in the circulation of HNSCC patients is reduced to less than half of 
the normal levels after chemoradiotherapy and remains decreased up to one year after treatment. 
Importantly, these low lymphocyte levels are associated with poor prognosis (54). A plausible expl-
anation is the sensitivity of CD4+ helper cells to cisplatin, aggravated by cisplatin-resistance observed in 
regulatory T lymphocytes. This imbalance between regulatory T cells and tumour-reactive T 
cells persists for several years after therapy (55). 
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Figure 6:	 Patient	 samples	 the	 involvement	 in	 the	 different	 experiments	 in	 Paper	 II.	 (A)	Tumour	
and	blood,	neutrophil	 subsets	 identification	and	 immunostaining	 (B)	Blood,	anti-tumour	 response	 
(C) Blood characterization of subsets with CD11b and CD18 and IL-8 assay and IL-8 stimulation 
(D)	Tumour	and	blood,	immunostainings	and	subset	identification
MATERIALS AND METHODS
This section contains a brief overview of the materials and methods used in the studies. More 
details can be found in the papers I-V.
Human Study Populations (Paper I-V)
Paper I: Blood from 58 patients with oropharyngeal cancer, (base of tongue or tonsil) was obtai-
ned prior to treatment. Blood from 90 healthy donors served as control.
Paper II: A total of 46 HNSCC patients have contributed with tumour biopsies and/or blood 
for this study (Figure 6). Blood from 20 patients before initiation of treatment, along with 19 
controls were used (A). Granulocytes were isolated from blood obtained from 12 untreated pa-
tients (C, eight of them were the same patients as in D, and four patients contributed only with 
blood). Tumour biopsies along with a blood sample were taken from 22 patients (D). Twelve 
biopsies were embedded in paraffin, sliced in 3 mm sections, and mounted on glass slides, and 
ten biopsies were used for flow cytometry analysis. Blood was also collected from 12 healthy do-
nors to determine the impact of activated neutrophils on the antitumor immune response (B).
Paper III: Tumour biopsies from 19 patients with tongue cancer were analysed. Sections of lymph 
nodes from their neck dissections were obtained at the same time, in six of them sentinel nodes 
were identified. Four non-cancer donors contributed with healthy lymph nodes when having 
benign neck surgery (Figure 7).
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Paper IV: 14 patients were investigated with sentinel node technique during surgery, 24 sentinel 
nodes were collected.
Paper V: Blood, tumour and lymph nodes from 30 patients with oral squamous cell carcinoma 
were included in this study. In 17 neck dissections sentinel lymph nodes were identified and 27 
sentinel nodes were found.
The studies were mainly performed at the Ear-, Nose- and Throat department at Karolinska 
Institutet and Karolinska University Hospital in Stockholm, a part of study II was performed at 
Skåne University Hospital in Malmö, after approval from the Ethics committee at Karolinska 
Institutet and/or Lund University. Written informed consent was obtained from all participants 
in these studies.
Figure 7:  
Tissue samples in Paper III and V  were 
collected from several loci from each 
patient, from the primary tumour in the oral 
cavity (1), from a lymph node (2) and from a known 
metastasis, when present (3). If a sentinel 
node procedure was done, samples were 
taken	 from	 first	 receiving	 lymph	 node,	 
together with a lymph node further down in the 
lymphatic draining system. When no lymph node 
metastases were suspected, a second lymph 
node	from	a	different	region	of	the	neck	than	the	
first	node	was	selected.
Cell Isolation (Paper II)
For cell isolation, Ficoll-PaqueTM was used to separate polymorphonuclear leukocytes (PMN) and 
peripheral blood mononuclear cells (PBMC) in blood.  PMN and erythrocytes with high density 
sedimented to the bottom of the tube, and PBMC with low density could be found at the 
interface of plasma (above) and Ficoll- PlaqueTM (below). To recover pure PMN the erythro-
cytes were lysed with ammonium chloride buffer. The cells were then cultured in RPMI-1640 
supplemented with 0.3 g/l L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% 
autologous plasma to a concentration of 4 X 106 PMN at 37°C in humidified 5% CO2. In pa-
per II PMN was isolated from blood of cancer patients and used in the granulocyte activation.
Tumour Cell Isolation (Paper III and V)
Tumour Dissociation KIT was used to mechanically and enzymatically dissociate surgical speci-
men in order to achieve a single cell suspension. A single cell suspension was needed in FACS. 
The tissue samples were cut into small pieces and treated with enzymes at 37oC in a special 
dissociator(Gentle MACS). After dissociation, the cells were filtered through a 100µm cellstrai-
ner. A wash step was performed, samples were centrifuged and the cells were re-suspended in 
stainbuffer.
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Figure 8:	(A)	Histogram	of	FITC	signal	fluorescence	from	a	tumour	sample	stained	either	with	anti	CK5/8	
(solid	black	line),	anti	EpCAM	(dotted	line)	or	anti	MUC-1	(dashed	line)	and	all	three	markers	stained	to-
gether	(solid	black	line).	(B)	The	gating	strategy	applied	in	FACS	data	analysis:	first	PI-positive	cells,	i.e.	
nucleated	cells,	were	gated	and	from	this	population	the	frequency	of	FITC	positive	cells	was	quantified.	
The	first	plot	shows	a	PI	gate	and	the	second	a	tumour	sample	with	FITC	positive	cells.
Flow Cytometry (Paper II-V)
Fluorescence activated cell sorting (FACS) is a method that analyses the physical and chemical proper-
ties of individual cells based on how they scatter light from a laser beam. Through different detectors 
flow cytometry gives information about cell size (displayed by forward scatter; FSc) and granularity 
(displayed by side scatter; SSc). Fluorescence intensity of flourochrome conjugated antibodies against 
extra- or intra cellular antigens provides information about the cell phenotype. It can simultaneously 
do multi-parametric analyses of physical and chemical characteristics in up to thousands of cells per 
second. Generated data from the flow cytometers can be plotted as a single dimension in a histogram, 
or as a two dimension dot plot based on two different parameters on the x and y axis. The regions on 
this plot can be separated based on fluorescence intensity and are called “gates” (Figure 8). The cells 
of a gate, a population, can be presented in relation to a specific group of cells, in absolute counts or as 
mean fluorescent intensity (MFI). In paper II we used Beckman Coulter Navios or a BD LSR Fortessa 
flowcytometer and data were analysed with either CXP analysis software or FlowJo software. In paper 
III and V the blood was lysed with ammonium chloride solution and washed with PBS and stained by 
antibodies before analysis in the FACS. We used FACS to distinguish the homogeneous mixture of 
cells into different groups according to their specific light scattering and fluorescent characteristics. It 
provides a physical separation of cells of a particular interest. Flow cytometry was performed on a BD 
Accuri cytometer and FACS data were analysed using FloJo software.
In paper I we used the routine leucocyte differential counts, the blood was analysed at the Karolinska 
University Hospital clinical lab. The leucocytes were differentially counted and a flow cytometric analy-
sis was performed using Sysmex XE 5000.
In paper II neutrophil subsets were characterized based on the expression of CD16 and CD62L, neut-
rophils were identified as CD16+ granulocytes and T-cells as CD4+ lymphocytes in flow cytometry.
In paper III and V antibodies CK 5/8, EpCAM and (MUC-1) were fluorescein isothiocyanate (FITC) 
conjugated and used in the flow cytometry analysis. The FITC fluorescent signal, obtained from each 
of the antibodies separately, and all three in combination, are demonstrated in figure 8A. To separate 
intact tumour cells from debris, propidium iodide (PI) was used.
In paper V cells were first gated to exclude debris with the FACS. Cells were gated based on expression 
of cell poulationCD3+CD4+ and CD3+CD8+ to detect T-cells. CD69, CD71, HLA-DR were analysed 
individually on CD4 and CD8 T-cells. PD-1 expression was analysed with mean fluorescence intensity 
(MFI-mean).
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Sentinel Node (Paper III-V)
The first lymph node or group of nodes that drains a cancer site is called the sentinel node(s). 
If a metastasis occurs this is where they are usually found.  To identify them; Technetium 
Tc99m were labelled with one of the tracers (Nanocoll®, GE-Healthacare) or Lymphoseek®, 
Tilmanosept, Cardinal Health)  and was injected around the tumour 16 hours before surgery. 
A SPECT/CT was performed at the morning of the surgery. Blue dye or Indocyanine green 
(ICG) was injected immediately preoperativel around the tumour. A camera with near infra-red 
light detected the fluorescein light from the ICG which makes the lymph node visible in the 
wound. A handheld gamma probe was used to localize the sentinel nodes according to their 
radioactivity. In paper III six patients were investigated with the sentinel node technique, in 
paper IV the sentinel node technique was gradually developed and evaluated and all included 
patients were invested with this technique. 17 patients were investigated with sentinel node in 
paper V. The sentinel node procedure was under development at our department during the 
studies, therefore the procedure slightly varied slightly between patients.
Histopathology and Immunohistochemistry (Paper II-V)
Immunohistochemistry is an antibody-based method to identify proteins in tissues and cells. In 
our studies, horseradish peroxidase (HRP) was used as detection enzyme. After incubation with 
a substrate diaminobenzidine (DAB), a positive immunoreactivity occurs and a brown colour 
can be seen. To provide contrast to the sections and to visualize the nuclei, the slides are usu-
ally counter strained with haematoxylin. To rule out unspecific background staining, negative 
controls for mouse and/or rabbit primary antibodies were used. This was done in paper II. In 
paper III and V the parts of the tumour specimens and neck dissection resections, that were 
investigated with flow cytometry, were submitted to routine clinical pathological examination 
and diagnosed according to the guidelines of our institution. All non-metastatic lymph nodes 
(N0) analysed with flow cytometry in paper III had additional histological and immunohisto-
chemistry staining to rule out false negative results of standard clinical pathological examination.
The sentinel nodes in paper III, IV, V were fixed in formalin and submitted to routine paraffin 
section microscopic examination. Three hematoxilin-eosin (H&E) stained sections were taken 
at three levels, 200 micrometre between the levels. Between level one and two the specimen 
was investigated with a broad spectrum cytokeratin (CKMNF116). After fixation of the tumour 
in the tongue biopsy, one paraffin section of the tumour fraction was examined with H&E- 
stained section and one with immunohistochemically for PD- L1 (clone SP263 - Ventana). The 
PD-L1 stained section included an external control. The immunoreactivity for PD-L1 in the 
tumour cells was quantified by visual assessment and categorized first in 3 intervals (<1%, >1% 
and <50%, >50% according to the clinical guidelines) by 2 pathologists. Secondly all the slides 
were revaluated and re-categorized in 10%-groups.
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Statistical Analyses (Paper I-V)
All statistical analyses were done with GraphPAd Prism version 6.01 (GraphPAd Softwere, 
LA Jolla, CA, USA) A p-value of < 0.05 was considered statistically significant and n equals 
the number of individual subjects. All plots show values with mean or mean ± standard error 
of the mean (SEM). In paper I a non-parametric Mann Whitney test and Fisher´s exact test 
were used and the area under curve (AUC) of a receiver operating characteristic (ROC) plot 
was calculated. In paper II for normally distributed unpaired data, the unpaired Student’s t-test, 
with Welch correction if the variance was non-homogenous, was used. One-way repeated me-
asures analysis of variance (ANOVA) with Tukey’s post-hoc test was used for comparison of 
more than two sets of paired data that were normally distributed and when two sets of paired 
data were compared the Student’s t-test was utilized. The survival function from survival data 
was estimated using Kaplan–Meier analysis, and a log-rank test was utilized to examine the sig-
nificance of the different survival distributions between the two groups. In paper III and V the 
D’Agostino-Pearson normality test was used to determine if data sets were normally distributed, 
and one-way ANOVA or the Kruskall-Wallis tests were chosen, depending on the distribution 
of the data. The Brown-Forsythe test was conducted to evaluate homoscedasticity. ROC curves 
were plotted to calculate the area under the curve and evaluate sensitivity and specificity. In 
paper V paired t test was used to compare paired groups of data. Wilcoxon signed rank test for 
non-parametric paired data. Linear regression and correlation have been done.
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RESULTS AND COMMENTS
Oropharyngeal Cancer Induces an Innate Inflammation (Paper I)
Blood from OPSCC patients displayed an increased number of neutrophils and monocytes 
whereas the lymphocytes were suppressed compared to in healthy controls. The neutrophil 
to lymphocyte ratio (NLR) and the monocyte to lymphocyte ratio (MLR) were calculated and 
patients with large tumours (T3-T4) exhibited a higher NLR and MLR compared to patients 
with small tumours (T1-T2) (Figure 9A). This was also true for the platelet to lymphocyte ratio 
(PLR). Patients with regional lymph node spread (N+) exhibited a lower NLR and MLR than 
patients with only local disease (N0) (Figure 9B). No correlation was seen between T and N 
stages when a Fisher’s exact test was applied to control for confounding factors. NLR was found 
to be lower in the HPV positive group than in the HPV negative group. 
Comments
NLR is used as a prognostic marker for many types of cancer (56,57). An elevated NLR befo-
re treatment has in several head and neck cancer studies been linked to poor overall survival 
(58,59). In one study an elevated NLR also exhibited a shorter disease specific survival (59). 
Figure 9: The NLR and the MLR in blood from 58 patients with OPSCC. The patients were divided ac-
cording	to	the	size	of	(A)	the	primary	tumour	(T1+T2	versus	T3+4);	and	according	to	(B)	their	lymph	node	
metastatic status (N0 versus N+).
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Figure 10: 5 years overall survival curve of oropharyngeal cancer patients with high NLR (n=23) 
and low NLR (n=23). High were above the mean (= 2,52) and low below mean. 
In a study on HPV induced oropharyngeal cancers, the overall survival (OS) for the high NLR 
group was 85.3% compared to the low NLR group with 96,3%. A high NLR was associated with 
advanced disease but did not reach significance. The high NLR group had  poor disease free 
survival (DFS) compared to the low NLR group (60). The reports cited above were published 
after our manuscript was published and due to differences in the endpoint selection it is hard 
to compare their results with our data. The 5-years overall survival in our study population was 
high (Figure 10). 47 out of 56 were still alive after 60 months. (Two patients were lost during the 
follow up period). The high NLR group had a survival rate at 84% and the low NLR group at 
80 %. In our study patients with N2b-N2c neck nodes seemed to have an increased amount of 
lymphocytes, resulting in a low NLR, compared to the patients with N0-N2, but the difference 
did not reach significance. This could be compare to a study where the patients with high NLR 
showed a reduced survival, especially among those with higher N stage. However, it is important 
to recognize that no N0 was reported in the study (60).
Further, in a study where NLR, PLR and LMR (lymphocyte to monocyte ratio) in laryngeal, 
oropharyngeal, and hypopharyngeal cancer were investigated it was found, similar to our study, 
that a high NLR (and a low LMR) correlated with large tumours (42). In contrast to our results 
they did not find any correlation between high PLR and large tumours. Kano et al divided 
the N-stage into groups of N0-N2a and N2b-N3 and found that NLR were higher with greater 
N stage which is exactly opposite compared to what we found. In our study the patients with 
lymph node metastasis had a lower NLR than the group without metastases. In the study by 
Kano et al. only LMR was independently correlated to overall survival. It is important to notice 
that the hypopharyngeal cancer patients usually were diagnosed at an advanced stage and had a 
higher mortality compared to patients with oropharyngeal cancer. The study included tumour 
specimens from 102 hypopharyngeal, 116 oropharyngeal and 67 laryngeal cancer patients (42). 
High PLR (in this case due to high platelets accounts) has been correlated to poor prognosis and 
anti-platelet treatment has been reported to improve the prognosis (61).
Lymphocytopenia corresponds to a high NLR and is more common in large tumours, so-
mething that has been linked to poor outcome (44,62,63). Previous studies from our group 
have demonstrated suppressed and anergic T lymphocytes in HNSCC (64). These lymphocy-
tes could not produce a proper immune response to avoid tumour progression. An increased 
amount of neutrophils in the blood is known to be related to a bad outcome (65) The same ap-
pears  to be true for high levels of intra tumoural neutrophils (66). A likely explanation for this 
might be that high levels of neutrophils result in a systemic activation of neutrophil extracellular 
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traps (NETs). NETs bind pathogens extracellularly in networks of fibres, primary composed 
from neutrophil elastase (58). 
To summarize, NLR is easy to measure with a blood test and can be used as a prognostic mar-
ker. The role of neutrophils in blood shows signs of systemic innate inflammation. But since 
the OS in HPV+ oropharyngeal cancer is high and the range of NLR is broad, the clinical use 
of the NLR in the individual patient is somewhat limited.
Neutrophil Subset can be used to Predict Survival (Paper II)
The three different neutrophil subsets CD16highCD62Ldim, CD16dimCD62Lhigh and CD16highCD62Lhigh 
were found in the circulation of patients with HNSCC (Figure 11). The patients exhibited a higher per-
centage of CD16highCD62Ldim neutrophils compared to healthy controls. The CD16highCD62Ldim subset 
displayed a distinct phenotype with high expression of CD11b and CD18.  
CD16highCD62Ldim was prone to migrate into the tumour, this was facilitated by tumour-derived IL-8. 
IL-8 was also found to activate neutrophils and to promote subset transition. Activated CD16highCD62L-
dim neutrophils had the ability to inhibit migration, proliferation and to induce apoptosis of FaDu cells. 
Neutrophil elastase detected in activated CD16highCD62Ldim neutrophils and tumour biopsies suggested 
that CD16highCD62Ldim neutrophils impart anti tumoural activity via NETs. Patients with a high number 
of CD16highCD62Ldim neutrophils had an increased survival rate (Figure12).
Figure 11:	Neutrophil	 subsets	 in	 patients	with	HNSCC.	Blood	was	obtained	 from	patients	with	 cancer;	
(n=20) and healthy controls (n=19), and incubated with antibodies against CD16 and CD62L. The neutrophil 
subsets	were	characterized	with	flow	cytometry.	*p	<0.05;	**p	<0.01;	***p	<0.001.
Figure 12:	A	Kaplan–Meier	analysis	of	HNSCC	
patients divided into two groups, based on their 
levels of CD16highCD62Ldim neutrophils in blood. 
A high level of CD16high CD62Ldim neutrophils 
indicated	an	improved	survival.	*p=0.05.	n=	20
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Comments
Neutrophils have a complex and diverse role in inflammation and in cancer immunology. They 
exhibit both pro- and anti-tumorigenic roles which seem to differ depending on the cancer type 
and the stage of the disease (67,68). In many cancer forms, including HNSCC neutrophils can 
promote metastases  (68–70).
There are many pro-tumorigenic mechanisms, initiation of tumour angiogenesis is one of 
them. Matrix metalloproteinase-9 (MMP-9) is secreted from neutrophils and leads to release of 
vascular endothelial growth factor (VEGF) from the extra cellular matrix (ECM) and VEGF 
induces angiogenesis. In lung cancer MMP-9 has been shown to inhibit apoptosis of cancer 
cells. Tumour associated neutrophils (TAN) release cytokines to induce chronic inflamma-
tion and arginase 1 which inhibits CD8+ T lymphocytes and weakens the tumour defence. 
High numbers of TAN are therefore usually associated with poor prognosis and advanced 
disease. Finally, reactive oxygen species (ROS) are normally used by the neutrophils to destroy 
microorganisms, but can also indirectly promote tumour growth.
The neutrophils also possess anti-tumour functions. Since the mechanisms involved in the 
anti–tumour function often are the same as in pro-tumour activity it is easy to become confused. 
However, the difference is related to disparities of timing and tumour form. Neutrophils are fast 
and have the potential to kill tumour cells, involve anti-microbial functions and immune regula-
tory functions. N1 is an anti-tumour phenotype of neutrophils, well studied in murine models. 
N1 cells can recruit and activate CD8+ T cells. Likewise, ROS appears to have the ability to 
eliminate tumour cells during their early development. Antibody Dependent Cell–mediated 
Cytotoxity (ADCC), is an effective part of the anti-tumour defence of the immune system. It 
represents an antibody directed towards tumour cells that binds to the immune cell often an 
NK cell but could also be a neutrophil. The antibody activates the cell to destroy the tumour 
cell.  Neutrophils could  express Tumour necrosis factor Related Apoptosis Inducing Ligand 
(TRAIL) on its surface and induce apoptosis of the tumour cell (68,69). The neutrophil seems 
to regulate the tumour to grow or to decline using more or less the same mechanisms but in 
different environments.
The presented work details the role of the different neutrophil subsets in HNSCC (40). It is 
our  belief that the different subsets seem to represent different stages of activation or matura-
tion.  CD16high-CD62Ldim neutrophils were found to be elevated in patients compared to healthy 
individuals. They represent a mature and activated form, capable to affect the tumour cells. 
The subgroup  CD16dimCD62Lhigh neutrophils have the characteristics of immature cells, from 
the bone marrow and CD16highCD62Lhigh are normal mature neutrophils. CD16dimCD62Ldim 
neutrophils were not found  in this study (Figure 2). We saw an association between IL-8 
activated CD16highCD62Ldim neutrophils and the formation of NETs. The latter seem to be 
responsible for the anti-tumour function. However, knowledge about NET formation and its 
role in tumour microenvironment is still very limited. In a recent review they described the 
function of NETs as part of a tumour progression rather than anti-tumour function (68).  
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In our study patients with a numerous CD16highCD62Ldim neutrophils had a better survival. The 
included patient tumours were all squamous cell carcinomas but located in different parts of the 
head and neck area, this might influence the survival of the patients and is a weakness of our study. 
A statistical analysis was performed to search for biases but none were found between, high and low 
CD16highCD62Ldim neutrophils. To summarize, neutrophils have an important role in the deve-
lopment of tumours. The subgroup CD16highCD62Ldim seems to increase migration and NET- 
formation with anti-tumour activity.  In addition, CD16highCD62Ldim neutrophils correlate with 
increased survival in HNSCC patients.
Cancer Cells Detection and Sentinel Lymph Node Procedure (Paper III- IV)
Paper IV establishes a protocol for sentinel node identification. To facilitate the planning of the 
surgery a preoperative (SPECT-CT) was performed. Nine out of 14 patients received nanocoll, 
a colloid commonly used in sentinel node detection, and four patients received tilamanocept, 
a new mannose based diagnostic radioactivity carrier. The carriers, nanocoll and tilmanocept 
were equipped with a radioactive, Techneticum99m isotop. One or the other was injected the 
day before surgery and in the morning the surgery day a SPECT-CT was done. In nine of the 
patients a 3D volume analysis was achieved using the SPECT-CT data, to better visualise the 
sentinel node. In contrast to nanocoll the use of tilmanocept resulted in a stabile nodal uptake 
with the radioactivity staying in the node for a long period. Hence, the latter was preferred by 
both the nuclear medicine physicist, making the 3D reconstructions and the surgeon.
Visual marking 
In breast cancer SLN procedure the routine for detection is to inject blue dye in the lymphatic 
system. However, in the neck blue dye has not given the same good results. Only one patient 
was included where blue dye was used in our study. In the other 13 patients we used fluorescen-
ce (ICG) for staining of the sentinel node. ICG was injected around the tumour at the start of 
surgery and during the surgery a near-infrared (NIR) light, a telescope and a camera specially 
adapted for the purpose was used to visualize the fluorescence from the sentinel node (71). 
Since the light from ICG only travels 10 mm in the tissue a hand-held gamma probe was used 
to localize the radioactivity. After identification of the sentinel nodes an END was performed. 
The sentinel nodes were divided in two by a pathologist. One part was analysed with immune 
histopathology in the routine pathology lab whereas the other part was processed using flow 
cytometry.
The concept we arrived at for identifying the sentinel node starts with the presurgical injection 
of radioactive technetium Tc99m carried on tilmanocept (Lymphoseek®) around the tumour. 
The radioactive uptake is visualized in the node the following morning, preoperatively with 
(SPECT-CT). In the beginning of the surgical procedure ICG is then injected around the tu-
mour and visualized with infrared light. To further support the sentinel node detection the 
surgeon, uses a hand held gammaprobe.
Markers for analysis
To be able to use flow cytometry for detection of tumour cells in the lymph node we needed to 
find the most reliable markers. We tried many different markers and combination of markers 
to get a reliable result. We needed to be sure that we could detect all the tumour cells that we 
put in the FACS. Many pre-studies were done before we applied for ethical permission to study 
patients. The conclusion was to use CK5/8, MUC-1 and EpCAM as markers since they are 
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epitopes common to the epithelial cells. Normal lymph nodes do not contain epithelial cells 
which are why and these markers can serve as markers for squamous cells including carcinoma 
cells. Using the three markers under the same fluorescence channel provided a good distinction 
between positive and negative events.
Two different FACS methods were tried, the first was based on universally applied sig-
nal strength and the second on an individually determined signal strength based on the 
background. The two strategies correlated well with each other. Therefore, we concluded 
that flow cytometry is a reliable method for analysing positive lymph nodes using predeter-
mined cut off levels (Figure 13). We calculated the level of detection based on the results 
from cancer-free lymph nodes from the control patients. The median rate of EpCAM/Ck8/
MUC-1 positive cells was 8, 1% in oral tumours and 3,9 % in histologically confirmed me-
tastatic lymph nodes. Metastatic lymph nodes could be reliably distinguished from non- 
metastatic nodes. 
Propidium iodine(PI), was used to mark the nucleus to distinguish tumour cells from debris 
in the flow cytometer (Figure 14). In this proof of concept study, lymph nodes from healthy 
individuals, resected while undergoing surgery for benign reason were used as controls. The 
control lymph nodes were analysed in the same way as the lymph nodes from tumour patients 
(Figure 14)
While this study was running the clinic decided to use the sentinel lymph node (SLN) techni-
que. We detected and investigated nine sentinel nodes and four of them scored above the level 
of detection. In the lymph nodes, where no sentinel node procedure was done, four lymph 
nodes had above level of detection out of 21. 
Comments
Flow Cytometry 
Flow cytometry is routinely used in the investigation of haematological cancers (72). In renal 
cell carcinoma flow cytometry has been effectively used in the search for micro metastases in 
sentinel lymph nodes (73). So far flow cytometry has not been used in the search for metast-
ases in lymph nodes in head and neck cancer patients. In this study we identified the tumour 
cells in the lymph nodes that we received after surgery. Since epithelial cells not normally 
are present in lymph nodes we used epithelial markers in the FACS to represent squamous 
carcinoma. There are rare examples of brachial arch remnants and cytokeratin positivity of 
interstitial reticular cells that can be seen in the lymph nodes and may be positive to any of the 
markers (74,75). During the process of metastasis carcinoma cells undergo epithelial-to-me-
senchymal transition and lose their expression of epithelial marker such as E-cadherin (76). 
The choice of markers is a balance between high sensitivity and an increase in false positive 
findings. 
Before we settled for CK5/8, EpCAM, MUC-1 we tried several other markers and combination 
of markers to find the best composition of antibodies. The best results were obtained when the 
antibodies were marked with the same colour and united into one channel in the FACS. This 
also gave us the opportunity to analyse the cells with additional markers at the same time in 
FACS. The antibodies used in the flow cytometer decide and limit the result of the investiga-
tion; with right antibodies the analysis is fast and distinct. The speed of flow cytometry enables 
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Figure 13:	 The	 frequency	 of	 epithelial- 
marker-positive cells in primary tumour 
samples, metastases, histologically non- 
metastatic nodes (N0 node), control lymph 
nodes from cancer-free individuals and 
sentinel lymph nodes (SLN). They are 
evaluated according to individually deter-
mined	 cut	 off	 levels	 for	 each	 sample.	 LOD= 
level of detection (3SD of healthy controls medi-
an). Y-axis is a log10 scale. 
Figure 14:	Details	of	flow	cytometry	method	(A)	Positive	metastasis	(B)	Negative	lymph	node.	(a)	FACS	
gated	for	propidium	iodide	(PI),	(b)	FACS	gated	for	epithelial	markers,	CK5/8,	EpCAM,	MUC-1	(c)	Photo-
micrograph	of	cells,	triple-stained	with	CK5/8,	EpCAM	and	MUC-1	FITS-	conjugated	antibodies	(green)	
and (blue)
a
b
c
  A                                                       B
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an analysis of the material from surgery within 3 h. The FACS analysis could be automatized 
which is an advantage.
In our study the pathologist divided the lymph node, a metastasis was usually seen without 
microscope, and could be cut in two and shared, one section was analysed with FACS and the 
other section was sent for regular histopathology.  Micro metastases (>0,2 mm in diameter) or 
isolated tumour cells  are small and could therefore be present in any of two the sections (2). 
Hence, the result from the histopathology and the flow cytometry could differ and both of them 
be true.
Finding Occult Metastases
In our clinic, stage II patients have occult metastases in 41 % and stage I patients in 6% (28). (In 
oral cancer Stage I equals to T1N0, Stage II equals to T2N0).  Treatment recommendations 
for this group of patients diverge between END and watchful waiting with therapeutic neck dis-
section if regional relapse of the disease. In a large study of patients were randomized to either 
END or watchful waiting with therapeutic surgery. Both overall survival and disease-free survi-
val were better in elective neck dissection group (27). The rate of metastases that is undetected 
by imaging and clinical investigation in T1-T2 oral cancers is about 20 % (26). Thus, about 80% 
have then received unnecessary surgery. Many studies indicate that a search for sentinel node 
could be an appropriate way to investigate the neck for metastases (78,79).  In our study, we 
found a raised number of tumour cells in the sentinel nodes. This result stress the importance 
to focus on the sentinel node. 
Sentinel Node
In breast cancer sentinel lymph node biopsy (SLNB) is a routine investigation and has been 
used successfully for a long time (80). The anatomy implies to more concerns in the SLNB 
procedure of the neck compared to the axillary area. The Sentinel European Node Trial 
(SENT) is a large European study including 415 oral cancer patients from 14 centres. In this 
study, the sensitivity for SLNB was 86% and the negative predictive value 95 % with only minor 
complication (3%). The authors encourage the clinical use of the SLNB technique (78). The 
post-operative complications  were investigated after SLNB and END, the overall result favou-
red the first,  even when the prognosis had been taken into consideration (81).It takes time to 
learn how to do a sentinel node detection, to attain a good result and to use the technical devices 
in an optimal way. ICG penetrates only 10 mm and thus has the drawback of not being visible 
deep in the tissue. Our experiences with ICG are that it penetrates different depths in different 
tissues, never more than 10 mm. Many lymph nodes in the neck region are situated in behind 
the sternocleidomastoid muscle and a gamma probe may be needed in the initial stage of the 
procedure.
We have used tilmanocept a new diagnostic tracer in this study. With tilmanocept a more dis-
tinct picture of the radioactive uptake can be obtained and it is possible to exclude the light of 
the radioactivity at the injection site when you visualize it in the computer, to get a better 3D 
picture of the sentinel node. This was important when tumours in the oral cavity had sentinel 
nodes in region I, which were hidden in the light of the injection site. We believe the future is 
to combine ICG with nanocoll Tc99m in one injection (82). In this study we wanted to describe 
how to get a reliable result with a reasonable logistics to find the sentinel nodes. The regular 
endpoint with sentinel node biopsy studies is to detect a positive or a negative lymph node and 
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thereafter decide on further surgery. All our sentinel node detection was followed by a neck 
dissection and our focus was to find the sentinel nodes and thereafter identify the metastatic 
cells with flow cytometry and in parallel search for immune markers to be able to select patients 
for immunotherapy (Figure 15).
Figure 15:	A	flow	chart	describing	the	sentinel	node	flow	of	today	(blue)	and		the	sentinel	node	flow	of	
the future (orange).
  
In the future we hope to indentify and bring out the sentinl node, analyse it with FACS, in the 
operating room, while the surgeron continue to resect the primary tumour of the tounge. The 
result of the FACS will then guide us, if we find a  positve lymph node we will continue with a 
neck disection, and if a negative lymph node is found, we will analyse the rest of the node with 
IHC. At the same FACS analyse we will stage the patient according to their individual immu-
nology.
Immunology staging using sentinel nodes (Paper V)
Tumour antigens activate T lymphocytes in the lymph node, which indicates the possibility to 
boost the immune response in the individual patient. The T cell activation varies with the in-
vestigated locations and tumour antigen exposure. The activation markers studied were chosen 
according to their differences in time for expression and thus their ability to indicate a time 
variance (83–86).
Lymphocyte Activation
The mean activation of T cells in our patients was high in tumours and low in blood, this pat-
tern was seen for all markers tested. The level of activated lymphocytes varied between patients 
in tumours and lymph nodes. The intermediate activation marker CD71+ was rare compared 
to the other markers studied. We correlated the CD4+ T cells with the CD8+ T cells in the 
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different locations.  CD4+CD69+/CD8+CD69+ in the tumour had a good correlation as well 
as CD4+CD69+/CD8+CD69+ and CD4+CD71+/CD8+CD71+ in the lymph node. CD4+CD71+/
CD8+CD71+ in the tumour had a significant positive correlation but CD8+CD71+ were generally 
low in number.  The percentage positive CD4 and CD8 T- cells in blood and positive to any of the 
markers tested was low compared to positive T cells in tumour and in lymph nodes. 
The Role of Sentinel Node
The sentinel nodes exhibited significantly higher percentage of CD69+ T lymphocytes compared to 
the regular lymph nodes but the metastasis group had the highest levels. We found more CD4+CD71+ 
T cells in the metastatic lymph nodes than in the non-metastatic lymph nodes (Figure16).  When the 
sentinel lymph nodes were compared with non- sentinel lymph nodes in the same patient, no patient 
in the sentinel node group had less than 20% of CD69+ T cells and all except two patients had a higher 
level in the sentinel nodes compared to non-sentinel lymph nodes (Figure 17). Further, the sentinel 
node seems to reflect the tumour, since a high level of CD71+ in the sentinel node resulted in a high 
activation of the CD4+CD71+ T lymphocytes in the corresponding tumour. 
Figure 16: Activated CD4+ or CD8+ T lymphocytes (A) CD69+ and (B) CD71+ in regular lymph nodes, 
sentinel lymph nodes and lymph nodes with metastases.  Sentinel nodes with metastases according to 
histopathologic analysis were placed in the metastasis group. In the group named lymph nodes includes 
non-sentinel nodes and all lymph nodes examined when no sentinel node procedure was performed. 
When	activated	with	HLA-DR	we	did	not	see	any	differences	between	the	groups	(not	shown).	Mean	is	
represented	by	a	solid	line.	*p<	0.05,	**	p<0.01,	***	p<0.001,	****p<0.0001
Figure 17: The percentage CD4+CD69+ cells of 
total CD4+T lymphocytes in sentinel nodes in 
relation to regular lymph nodes of the same patient. 
When data from more than one node, in the groups, 
were available a mean value was calculated. Other 
CD4+ T cells as well as CD8+ T cells, studied with the 
activation	markers	CD71	and	HLA-DR,	did	not	differ	
between	the	groups	(not	shown).	*p<0.05
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Figure 18: Levels of MFI PD-1 in CD4+CD71+ T cells and CD8+CD71+ T cells in (A) the sentinel nodes and 
in (B) the tumours of the same patients. n=6, one of the tumour samples was not analysed due to technical 
reasons	*p<0.05,	**	p<0.01
 PD1/PD-L1 Pathway
The PD-1/PD-L1 pathway is in focus for immunotherapy in head and neck cancers (87–90). 
Tumour cells express PD-L1 on their surface. We divided the tumours into groups containing 
10% positive PD-L1 tumour cells, 20% positive cell and so on. We could not find any correla-
tion between PD-L1 positive tumour cells and the activated T lymphocytes in the same tumour. 
We further investigated Tlymphocytes for PD-1 expression in six patients. The CD8+CD71+ 
lymphocytes in the tumours were positive to PD-1 and significant higher than in the CD4+CD71+ 
lymphocytes. In the sentinel lymph nodes of the same patients, we could not find any difference 
between CD4+ and CD8+ T lymphocytes (Figure 18). 
Comments
In this study we focused on T cells activation in oral cancer patients and the use of the lymph 
nodes as a source of information. The essential role of the lymph node in tumour immuno- 
logy has been described in many studies (49,89). The T cell response and the T cell activation 
occur in the lymph node. The micro milieu for the tumour is central  and the balance between 
co-inhibitory (eg PD-1, CTLA-4)  and co-stimulatory (eg OX-40,CD28)  factors is important for 
the individual immune response (90). In a persistent tumour antigen exposure the CD8+ cell 
can be exhausted and express increased levels of inhibitory receptors such as PD-1 (91,92). It is 
hard to know if the CD8+ cells in the tumour have preserved functions or if they were exhausted 
and had lost their normal capacities.
Patients with many TIL mainly CD8+ cells,  in the tumour has been shown to have a good 
prognosis in many types of cancer as well as in head and neck cancer (46,93–95). In tumours, 
the lymphocyte activation profile demonstrated a high early (CD69) activation of CD8+ T cells 
which results in a low CD4CD8 ratio (Figure 19 B)  and thereafter a shift towards a low number 
of later (CD71) activated CD8 T cells (corresponding to a high ratio of CD4/CD8 T cells). This 
could be a result of a reduced development of CD8+ cells in the tumour or infiltration of CD4+ 
cells to the tumour from the lymph nodes.
Starska et al studied the T cell activity (CD69, CD71) with flow cytometry in blood and laryn- 
geal cancer tissue and their results resemble ours, the T cell activity was intense in both CD4+ 
and CD8+ cells when adding  laryngeal tumour antigens (85). They did not do lymph node 
studies. 
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Figure 19: Ratio of CD4+/CD8+ T lymphocytes in relation to their expression of CD69+ and CD71+ in the 
lymph	nodes	(A)	and		the	primary	tumour	(B).	The	dotted	line	represents	a	cut	off	(=1)	where	the	number	
of CD4+	equals	the	number	of	CD8+	cells.	Note:	The	significance	was	not	affected	by	the	outliers.	Mean	
is	represented	by	a	solid	line.	*p<0.05,	**	p<0.01,	***	p<0.001,	****p<0.0001.	
Straka et al. have used the transferrin receptor 1, CD71 a marker involved in the metabolism 
of iron, in their studies for T lymphocyte activation and so did we. It takes about 12 h for the 
receptor to be expressed at the surface of the activated T lymphocyte (83,96). The choice to 
use CD71 in our study has several reasons. In immunology the timing of a process is important 
and we wanted to use markers that developed at different points of time, the CD69 marker 
takes about half the time to develop at the surface as the CD71 marker. The surface expression 
of CD71 facilitates the use of flow cytometry. In earlier studies CD71 has been considered to 
express cell proliferation, and has been correlated to Ki 67, a well known intracellular marker 
(86,97–99). It is tempting to hope that that CD71 could be an easy traced marker for activated 
T cells, proliferation and anti-tumour defence.
Immunology in Sentinel Nodes
We have focused on the sentinel nodes to investigate the immune responses to passing tumour 
antigens. All patients had a reaction in the sentinel nodes compared to the lymph nodes further 
down in the lymphatic draining system, none of the patients had less than 20% CD69+CD4+ 
cells in their sentinel nodes (Figure 17). It is conceivable that patients with a higher percentage 
activated T cells in the sentinel nodes than in the non-sentinel nodes (lymph nodes) have a 
better prognosis. We had two patients going in the opposite direction but none of them have 
one year after completed therapy shown any tendency to relapse. 
PD-1/PD-L1 Pathway 
PD-L1 expressed at the tumour cell, can be visualised with IHC and in our study positive cells 
were counted by the pathologist. The PD-L1 expression has been used to guide patient selec-
tion for PD-1/PD-L1 inhibitors. In many clinical studies the tumours were divided in groups 
of <1%, >1% and >50% of positive PD-L1 cells (88,100). This is the routine procedure at 
our pathology lab.  We looked for an association between PD-L1 and the percentage positive 
CD71+T cells we had in our TILs. We could not find any association with the positive PD-L1 
cells divided as above.  To be sure of no association we re-evaluated the groups into groups of 
10% positive PD-L1 cells < 1%, 1-10%, 10-20 % and so on. No association between the CD71 
activated T cells in tumours and the expression of PD-L1 at tumour cells could be found. 
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A link between PD-1 at the T lymphocyte and PD-L1 on the tumour cell is needed to get a 
response of checkpoints inhibitors. Today PD-L1 is used for patient selection for treatment and 
in clinical trials. In one recent study 36% of the tumours included were positive for PD-L1(101) 
A tumour was classified in this study as positive when >5% of the tumour cells were PD-L1 po-
sitive.  This result was comparable to other studies (18.5-45%)(102,103) all of them were using 
the 5% limit and only oral cavity cancers were included.  Interestingly, some studies reported of 
a higher number of PD-L1 positive tumours in oral cancer in females than in men (102,104). 
In a study of HPV negative oral cancers they looked at PD-L1 gene expression. 45% of the 
tumours were positive to PD-L1 in IHC and in 19% of the cases a CD274/PD-L1 gene ampli-
fication was detected.  CD274/PD-L1 gene amplification and positive PD-L1 immunostaining 
was only associated in 73% of the cases and concordance of PD-L1 expression in tumour and 
metastasis were only 72% (103). 
In our study we could not find any correlation between CD71 expression and PD-L1 positivity 
in IHC.  It is important to remember the there is a lot of differences in the various methods 
for  PD-L1measurements today (87). On the immunostained slides  there is often a hetero- 
genic picture, and  the intensity of the staining may differ in different sections of the tumour and 
between patients (102). However,  in many studies there is a correlation between high level of 
PD-L1 and worse outcome (101,103,104). 
Taken together, PD-L1 in IHC is today an available marker for patient selection, it has a lot of 
short comings and better markers are needed. The activation pattern in T lymphocytes in the 
sentinel nodes differs from other lymph nodes and the T cell activation in the sentinel node 
seems to follow the activation pattern of the tumour. Investigation of the T cell activation 
pattern in the sentinel nodes gives us an immunology stage of the individual patient and it might 
reflect the ability of the patient to respond to immunotherapy. Flow cytometry could therefore 
have an important role in the analysis of PD-1/PD-L1 pathway. 
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FUTURE PERSPECTIVES
Therapies that affect the immune system to eradicate a cancer disease are here to stay (88). In 
last years the so-called checkpoints inhibitors have emerged as an important strategy for treating 
relapses of head and neck cancer, but not all patients respond to therapy (101). The need for 
better patient selection is clear. In this thesis we have tried to elucidate the role that lymph 
nodes play in the immune response to head and neck cancers. 
It is clear that the microenvironment is involved in the tumour progression. Recent research 
shows that HPV positive oropharyngeal tumours have a different pattern of progression then 
HPV negative tumours. Hence, it could be of interest to study these two groups separately 
according to their different immunology. It is unclear whether neutrophils promote or prevent 
the development of cancer. It is also unclear if the aggressiveness of the tumour leads to changes 
of the immune status or the neutrophils and the monocytes contribute to the aggressiveness of 
the tumour. 
A neutrophil lives for a limited time and a cancer disease takes months or maybe years to 
develop. Since the neutrophils cohort  change, it is also possible for the role of the neutrophil 
to change during the tumour progression and maybe that could explain the pro-tumorigenic 
and the anti-tumorigenic features the neutrophil can take (68). The activated CD16highCD62Ldim 
neutrophils showed anti-tumorigenic characteristics and patients with high levels of this subtype 
showed increased survival. It would be interesting to verify this with a large cohort of homo- 
genous cancer patients. 
 
To use of FACS to detect tumour cells in lymph nodes of oral squamous cell carcinoma has not 
previously been done. Before clinical implements can be realized, the FACS gating has to be set 
and standardized with a large cohort. If flow cytometry analysis of lymph nodes becomes routi-
ne, many kinds of immunology studies can be done and immunology staging be a possibility.
The techniques of sentinel node are constantly improved. Dynamic investigations with SPECT–
CT could reveal if a sentinel node is a single first receiver of tumour antigens or if there are 
several nodes in a paralleled system. Our studies showed many SN far from the primary 
tumour area in region IV and V or at the contralateral side. If a limited neck dissection without 
SN had been applied, several of these distant nodes would probably have been missed. 
The future is in personalized medicine. To further investigate the correlations between activated 
T cells and the inhibitory pathways will be needed. To stage the oral cancer patients according 
to their immunology status in the lymph node would equippe us with a new diagnostic tool.
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CONCLUSIONS
- Patients with oropharyngeal cancer displayed signs of increased systemic inflam-
mation. Generally, large tumours seemed to be associated with a high neutrophil 
to monocyte ratio whereas patients with metastatic node spread showed a low 
corresponding value.
- A specific neutrophil subset, CD16highCD62Ldim appeared to have anti-tumour pro-
perties, with the ability to inhibit cancer cell migration and proliferation and to induce  
apoptosis. Further, the elastase in the activated neutrophils created neutrophil extra- 
cellular traps (NET) and a high rate of CD16highCD62Ldim neutrophils correspon-
ded to a better survival. 
- Flow cytometry could be used to detect cancer cells in lymph nodes. The results could 
be presented within 6 hours from the time of biopsy and the data correlated with the  
clinical histopathologic investigation performed in parallel. The results indicated 
that flow cytometry could be a very sensitive tool to find micro metastases.
- Various techniques for identification of sentinel nodes in oral cancer were evalu-
ated in a clinical setting.  A combination of techniques was found to constitute a 
reliable, clinically feasible work concept. An injection of radioactive technetium 
Tc99m carried on tilmanocept started the process. The lymph nodes were visua-
lized with SPECT/CT before surgery and with ICG fluorescence dye in combina-
tion with a hand-held gamma probe during surgery. 
- Lymph node metastases in oral cancer exhibited a higher level of activated T cells than 
cancer free lymph nodes. CD69, a marker of T cell activity was generally higher in  
sentinel lymph nodes than in regular nodes. PD-L1 on tumour cells did not cor-
relate to the expression of activation markers on T lymphocytes in the tumour. 
CD8+ T lymphocytes with high CD71+PD-1 expression were more abundant in 
the tumours than in the sentinel nodes. Altogether this indicates that immunolo-
gic activity of the sentinel node might prove useful to predict response and select 
patients for immunological treatment.
42 43
POPULÄRVETENSKAPLIG SAMMANFATTNING
Antalet patienter med huvud- och halscancer ökar i Sverige och omkring 1300 personer insjuk-
nar årligen. Cancern kan behandlas framgångsrikt om de upptäcks i tid. I ungefär en tredjedel 
av fallen har tumören spridit sig redan vid första läkarbesöket. Behandlingen styrs av tumörens 
storlek, lokalisation och eventuell spridning. Det är viktigt att få korrekt diagnos. Spridningen 
till halsens lymfkörtlar kan vara svår att upptäcka, hörnstenen är mikroskopisk undersökning av 
bortopererade lymfkörtlar. Metastaser som inte upptäcks leder till återfall av cancern, kan vara 
svåra att behandla och leda till kraftig funktionsnedsättning eller död. 
Vårt immunförsvar reagerar på cancerceller och sedan några år tillbaka finns läkemedel som 
stärker förmågan för vårt immunoförsvar att döda cancerceller. Behandlingen är dyr, biverk-
ningarna många och endast en mindre del av alla patienter svarar på behandlingen. Det krävs 
därför nya diagnostiska verktyg för att avgöra vilka patienter som bör behandlas. Stora resurser 
läggs ned för att hitta lämpliga markörer i blod och tumör för att göra denna selektion. Få tycks 
arbeta med lymfkörtlarna, den plats där den egentliga immunologiska reaktionen äger rum.
Denna avhandling undersöker det immunologiska samspelet mellan huvud-halscancer och 
immunologiskt verksamma celler som återfinns i blod, tumör och lymfkörtlar. Första delen 
fokuserar på neutrofiler, vita blodkroppar viktiga för vårt medfödda snabba immunförsvar. Vi 
utreder om flödescytometri, en cellanalys som länge avänts för diagnostik av blodcancer också 
kan användas för att hitta skivepitelcancerceller, lymfkörtelmetastaser vid munhålecancer mer 
specifikt. Avslutningsvis undersöks om det går att utnyttja det immunologiska svaret i lymfkört-
larna för att avgöra vem som är lämplig för nya former av immunologisk cancer terapi.
Det första delarbetet visar att antalet neutrofiler i blodet ökar när man drabbas av cancer i mun-
hålan. Detta kan tolkas som att patienten utvecklat ett inflammatoriskt svar på cancern. Det 
neutrofila inflammationsvaret visade sig vara tydligt relaterat till tumörens storlek. 
Neutrofila celler kan vara inaktiverade eller aktiverade. De senare har en betydligt större 
förmåga att påverka omgivningen än de förstnämnda. Det andra delarbetet visar att en 
speciell typ av aktiverade neutrofiler, CD16highCD62Ldim, förekommer vid cancer. Patienterna 
delades upp i två grupper, en med höga värden CD16highCD62Ldim neutrofiler och en med låga 
nivåer. Patientgruppen med höga nivåer visade sig leva längre. Det är därför frestande att anta att 
CD16highCD62Ldim på något sätt hämmar cancerutvecklingen.
Delstudie tre visar hur flödescytometri kan användas för diagnostik av lymfkörtel metastaser 
på halsen vid cancer i munhålan. Fördelen med denna metod är att den går snabbt, kan auto-
matiseras och att den samtidigt ger möjlighet att analyserar lymfkörtelns immunologiska profil. 
Vi valde att använda markörer för epitelceller som normalt inte finnas i lymfkörtlarna och som 
därmed väl representerar förekomst cancerceller. Det gick att visa att den nya metoden var 
minst lika bra på att hitta metastaser som den tidskrävande standardmetod används som idag 
används rutinmässigt.
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De lymfkörtlar som mest intimt kommunicerar med en tumör via lymfbanor benämns vanligen 
portvaktskörtlar eller sentinel nodes. De är de första körtlar som tar emot metastatiska celler 
som sprider sig från tumören är de vanligen där som de första metastaserna etableras och åter-
finnes. Det är också i portvaktskörtlarna som immunförsvaret först reagerar på förekomst av 
tumörceller. De är därför viktiga av diagnostiska skäl. Arbete fyra beskriver hur man rent prak-
tiskt kan gå till väga för att identifiera dessa portvaktskörtlar före och under operation.
I det avslutande arbetet kartläggs det immunologiska svaret i lymfkörtlar jämfört med det i 
blod och tumör vid munhålecancer. Vi har speciellt fokuserat på skillnader mellan portvakts- 
körtlar, körtlar som innehåller metastaser och övriga lymfkörtlar. De data som redovisas kan ge 
ledtrådar, inte bara om prognos utan också om vilka patienter som lämpar sig för immuno- 
logisk cancerterapi.
Sammanfattningsvis kan sägas att denna avhandling ser på huvud-halscancer ur ett immuno- 
logiskt perspektiv, där cancersjukdomen bedöms som en inflammatorisk sjukdom som 
engagerar vårt immunförsvar. De resultat som redovisas öppnar vägen för nya möjligheter till 
diagnostik och terapi. Det är vår förhoppning att vi genom denna forskning bidragit något till 
att cancer i huvud-halsregionen skall kunna gå samma gynnsamma utveckling till mötes som 
många former av blodcancer redan gjort.
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